Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval

Stock Track

2025/11/28

Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.

The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.

Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1116260561"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116260561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116260561?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116260561","market":"sg","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval","media":"Stock Track","content":"<p>Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.</p><p>The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.</p><p>Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-28 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.</p><p>The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.</p><p>Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1116260561","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116260561","pubTimestamp":1764341065,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股赛道|燃石生物盘中大涨5.44%因跌幅收窄及日本获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}